The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care

BACKGROUND: The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness, safety and healthcare utilization of empagliflozi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Endocrinol Diabetes Metab
Главные авторы: Patorno, Elisabetta, Najafzadeh, Mehdi, Pawar, Ajinkya, Franklin, Jessica M., Déruaz‐Luyet, Anouk, Brodovicz, Kimberly G., Santiago Ortiz, Adrian J., Bessette, Lily G., Kulldorff, Martin, Schneeweiss, Sebastian
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2019
Предметы:
Original Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6947693/
https://ncbi.nlm.nih.gov/pubmed/31922030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.103
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы